Genentech has made 11 presentations on new data regarding OCREVUS (ocrelizumab) and multiple sclerosis (MS) during the 69th American Academy of Neurology (AAN) annual meeting, which continues through Saturday in Boston.
The data described the effect OCREVUS had on patients with relapsing forms of MS (RMS) and primary progressive MS (PPMS). The RMS patients saw rapid improvement in the first eight weeks of treatment. It also had a positive effect on disease progression and fatigue in PPMS patients.
Genentech's leading investigators gave four oral and seven poster presentations during the annual meeting. OCREVUS is administered intravenously every six months, beginning with two 300 mg infusions two weeks apart and followed by singe 600 mg infusions. It was approved for treating RMS and PPMS by the U.S. Food and Drug Administration on March 28.
“OCREVUS is the only disease-modifying therapy approved by the FDA for people with primary progressive MS and offers people with relapsing MS a new treatment option with a favorable benefit-risk profile,” Genentech Chief Medical Officer Dr. Sandra Horning said. “The data being presented at AAN will demonstrate how rapidly OCREVUS controls disease activity and reduces brain MRI lesions in people with early RMS, both of which are important goals of treatment.”
Alerts Sign-up